Table 1.
Baseline clinical characteristics, laboratory data and outcome of patients with COVID-19.
| Variable | Treatment Group of Patients, n = 23 | Control (Historical) Group of Patients, n = 22 | All Patients, n = 45 | p |
|---|---|---|---|---|
| Age Median (Range) | 57 (31–72) | 62.5 (20–80) | 59 (20–80) | p = 0.58647 (OR = 1.422) |
| Male n (%) | 14 (61) | 14 (64) | 28 (62) | p = 0.84824 (OR = 1.125) |
| Female n (%) | 9 (39) | 8 (36) | 17 (38) | |
| Diagnosis | ||||
| Acute Leukemia/MDS EB2 n (%) | 14 (61) | 9 (41) | 23 (51) | p = 0.53659 |
| Chronic Lymphocytic Leukemia/Indolent Lymphoma n (%) | 2 (8.7) | 4 (18) | 6 (13) | |
| Aggressive Lymphoma n (%) | 4 (17) | 4 (18) | 8 (18) | |
| Multiple Myeloma n (%) | 2 (8.7) | 4 (18) | 6 (13) | |
| Other * n (%) | 1 (4.3) | 1 (4.5) | 2 (4.4) | |
| Hematologic Malignancy Status | ||||
| First Line Treatment | 11 (48) | 8 (36) | 19 (42) | p > 0.05 |
| Relapsed or Progression | 7 (30) | 9 (41) | 16 (36) | |
| Remission | 5 (22) | 5 (23) | 10 (22) | |
| Comorbidities | ||||
| 0 (%) | 4 (17) | 3 (14) | 7 (16) | p = 0.72828 (OR = 1.333) |
| 1–2 (%) | 5 (22) | 3 (14) | 8 (18) | p = 0.47729 (OR = 1.759) |
| ≥3 (%) | 14 (61) | 16 (73) | 30 (67) | p = 0.39896 (OR = 1.714) |
| Symptoms | ||||
| Fever n (%) | 15 (65) | 15 (68) | 30 (67) | p = 0.00665 (OR = 3.273) |
| Dyspnea n (%) | 12 (52) | 15 (68) | 27 (60) | p = 0.03008 (OR = 2.032) |
| Cough n (%) | 13 (57) | 10 (45) | 23 (51) | p = 0.00763 (OR = 3.333) |
| Other ** n (%) | 6 (26) | 12 (55) | 18 (40) | p = 0.03723 (OR = 2.252) |
| COVID-19 Pneumonia n (%) | 17 (74) | 18 (82) | 35 (78) | p = 0.02480 (OR = 8.772) |
| Laboratory Results | ||||
| WBC [g/L, m(range)] | 3.4 (0.01–36.02) | 3.5 (0.02–44.7) | 3.5 (0.01–44.7) | p = 0.04738 (OR = 3.02) |
| Lymphocytes [g/L, m(range)] | 0.6 (0.01–5.87) | 0.6 (0.02–3.5) | 0.6 (0.01–5.87) | p = 0.10452 (OR = 1.105) |
| Neutrophiles [g/L, m(range)] | 2.3 (0.01–11.78) | 2.3 (0.01–15.8) | 2.3 (0.01–15.8) | p = 0.08154 (OR = 2.631) |
| Platelets [g/L, m(range)] | 73 (1–473) | 79 (1–511) | 79 (1–511) | p > 0.05 |
| Hgb [g/dL, m(range)] | 9.65 (4.9–13.2) | 9.7 (6.9–13.7) | 9.7 (4.9–13.7) | p = 0.14940 (OR = 1.412) |
| CRP [mg/L, m(range)] | 32 (0.5–306) | 32 (2–350) | 32 (0.5–350) | p = 0.01415 (OR = 1.730) |
| SpO2 [m(range)] | 97 (70–100) | 97 (75–100) | 97 (70–100) | p > 0.05 |
| COVID-19 Severity | ||||
| Mild n (%) | 12 (52.2) | 6 (27.3) | 18 (40) | p = 0.03807 |
| Moderate n (%) | 6 (26.1) | 3 (13.6) | 9 (20) | |
| Severe n (%) | 5 (21.7) | 13 (59.1) | 18 (40) | |
| Duration of SARS CoV-2 Infection [days, m(range)] | 18 (8–28) | 37 (20–53) | 21 (8–53) | p = 0.00001 (OR = 6.056) |
| Treatment | ||||
| Oxygen Therapy n (%) | 15 (65.2) | 16 (72.7) | 31 (68.9) | p = 0.02355 (OR = 1.403) |
| High-Flow Nasal Oxygen n (%) | 1 (4.3) | 5 (22.7) | 4 (8.9) | p = 0.06983 (OR = 6.471) |
| Mechanical Ventilation n (%) | 3 (13) | 4 (18.2) | 7 (15.5) | p = 0.39295 (OR = 2.857) |
| Fresh Frozen Plasma n (%) | 23 (100) | 0 (0) | 23 (51.1) | N.D. |
| Hydroxychloroquine n (%) | 0 (0) | 22 (100) | 22 (48.9) | N.D. |
| Dexamethasone n (%) | 8 (34.8) | 12 (54.5) | 20 (44.4) | p = 0.18231 (OR = 2.250) |
| Other Treatment (Remdesivir, Tocilizumab, Lopinavir/Ritonavir) n (%) | 0 (0) | 3 (13.6) | 3 (6.7) | N.D. |
| Clinical Outcome, Death n (%) | 3 (13) | 9 (41) | 12 (27) | p = 0.03460 (OR = 4.615) |
* ITP—Immune thrombocytopenic purpura, aplastic anemia; ** diarrhea, nausea and vomiting, loss of smell and taste, conjunctivitis; n—number; N.D.—Not Determined.